SCHEMBL25514178

SCHEMBL25514178

Cc1cc2c(n1Cc1ccc(N)cc1)CCCC2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.54
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 1/20 0.47
PABPC1 P11940 1/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47
HTR6 P50406 2/20 0.42
HDAC1 Q13547 3/20 0.40
HDAC6 Q9UBN7 3/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
HPGD P15428 3/20 0.38
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 2/20 0.36
TYMS P04818 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25514004 0.87 BRD4 (0.52) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL25514185 0.86 BRD4 (0.54) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL21410145 0.84 BRD4 (0.77) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL25514182 0.83 BRD4 (0.51) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL25514199 0.83 BRD4 (0.51) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL25514196 0.83 BRD4 (0.54) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL21423949 0.75 BRD4 (0.79) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL11893025 0.73 SMN1; SMN2 (0.49) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL22916953 0.72 BRD4 (0.73) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1
SCHEMBL1053390 0.71 HPGD (0.50) BRD4ALDH1A1SMN1; SMN2MEN1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 BRD4 2025/4885ALDH1A1 199/4885SMN1; SMN2 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.